The risk factors of acquired long QT syndrome (aLQTS) are sometimes overlooked in clinics. Drugs, hypokalemia, age and female sex are well-known risk factors of QT prolongation-dependent torsade de pointes (TdP), which explains the high incidence of sudden cardiac death in LQT patients. Here, we report a case of an elderly female patient with lung cancer who was in poor condition, for whom amiodarone was mistakenly prescribed to rectify premature ventricular contractions. QT prolongationdependent TdP immediately followed intravenous injection of amiodarone. Fortunately, the patient survived aborted sudden cardiac arrest after effective cardio-pulmonary resuscitation and electric defibrillation. Upon reviewing the clinical information, several pre-existing risk factors of aLQTS and TdP were identified. The mistaken prescription of amiodarone provoked TdP after these risk factors were overlooked in this case and thus predisposed this patient to a high susceptibility of drug-induced TdP.
INTRODUCTION
Drug-induced long QT syndrome (LQTS) is the most common type of acquired long QT syndrome (aLQTS). It has been proposed that a fraction of individuals with borderline, or even normal QT-intervals, but in possession of risk factors of QT prolongation, are predisposed to life-threatening arrhythmias due to drug exposure [1] . End-stage diseases or poor conditions such as multiple organ failure, dyscrasia, hypoxia, and disturbance of acid-base and electrolyte balances, predispose patients to outbursts of malignant arrhythmias or even sudden cardiac death (SCD). Torsade de pointes (TdP) is a kind of polymorphic ventricular tachycardia (VT) that results from QTc prolongation, particularly more than 500 ms [2] .
Amiodarone used to treat atrial and/or ventricular arrhythmias [3] and verified to reduce mortality in sufferers with structural heart malfunctions [4] . Administration of intravenous amiodarone has been reported to cause TdP in some patients who have a reduced repolarization reserve, which is a risk factor for TdP [5] . Here, we report a patient with advanced nonsmall cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), and chronic heart failure (CHF), who developed TdP following the mistaken administration of intravenous amiodarone for premature ventricular contractions (PVCs).
CASE REPORT
An 85-year-old woman was transferred to our emergency department due to respiratory failure. Electrocardiogram (ECG) in the emergency department displayed a sinus rhythm of 100 bpm, QT interval of 400 ms and QTc of 516 ms (Fig. 1 On the second day after admission, the patient experienced several PVCs (originally ECG not obtained). Mistakenly, intravenous injection of amiodarone (1 mg/min) was then given to rectify the arrhythmia. After approximately half an hour, ECG monitoring showed TdP (Fig. 3) . Electrical cardioversion was utilized immediately. Ultimately, the patient survived from aborted SCD and regained sinus heart rate. (Fig. 4) .
DISCUSSION
The pathophysiological foundation of LQTS depends on reduced electrical stability in the ventricle with increased APD heterogeneity [2] . The increased inward currents prolong phase 2 repolarization, then promote the occurrence of early and delayed afterdepolarizations (EADs and DADs), thus increasing the transmural dispersion of ventricular repolarization and leading to spontaneous diastolic depolarization. This cascade reaction promotes the spatial and temporal dispersion of ventricular repolarization, ultimately causing arrhythmic events that manifest as TdP on an ECG [6] . TdP can be initiated by types of ventricular arrhythmias [7] . A so-called 'pause dependent' phenomenon is a typical mode of onset of TdP in patients with acquired or congenital LQTS [8, 9] . The sudden change in ventricular activation does not allow for the accurate adaptation of ventricular APD; it reduces the repolarization reserve of the ventricle and thus possibly leads to TdP [7, 10] .
Amiodarone has all four classes of electrophysiological features because it blocks various ion channels, such as I Kr , I Ks , I Na , I CaL and I to , as well as adrenergic receptors and alpha receptor nuclear T3 receptor [11] . Amiodarone possesses antiarrhythmic effects in most cases, but also leads to a low prevalence of drug-induced TdP in some special cases [4, 12, 13] . In this case, there were multiple risk factors reducing repolarization reserve, but were overlooked. The patient was given mezlocillin sodium and sulbactam sodium as antibiotics; the adverse effects of these antibiotics with regard to cardiomyocytes and QTc prolongation have not been found in the literature. Other conventional treatments, particularly potassium and calcium supplements, were employed to maintain the balance of electrolytes. However, this patient received antineoplastic gefitinib with the potential of prolonging the QT interval [14, 15] , and other risk factors facilitating drug-induced TdP included old age, female sex, hypokalemia, infection, COPD and CHF. All these factors predisposed this patient to the potential of QT prolongation-induced TdP. After amiodarone was mistakenly prescribed, TdP occurred. We calculated the score according to the Naranjo algorithm to evaluate the potential of amiodarone; the patient received a score of 4, suggesting possible adverse drug reaction due to amiodarone (Table 1) [16] . Therefore, amiodarone provoked TdP after being combined with risk factors that already existed.
Work has been done in this field with tools such as CiPA (Comprehensive in vitro Proarrhythmia Assay) to state the clinical risk of acquired arrhythmia; however, some clinicians are unaware of this important topic, unfortunately putting their patients to a high risk of drug-induced TdP, which can have fatal consequences. Are there previous conclusive reports on this reaction? 1 Did the adverse events appear after the suspected drug was given? 2 Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? 1 Did the adverse reaction appear when the drug was readministered? 0 Are there alternative causes that could have caused the reaction? −1 Did the reaction reappear when a placebo was given? 0 Was the drug detected in any body fluid in toxic concentrations? 0 Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? 0 Did the patient have a similar reaction to the same or similar drugs in any previous exposure? 0 Was the adverse event confirmed by any objective evidence? 1
